Document Type

Article

Disciplines

Pharmacology and pharmacy

Publication Details

https:// doi.org/10.4155/tde-2022-0066

Therapeutic Delivery, vol.14, no. 1, pg. 11–16.

Abstract

Company news Bend Bioscience invests in expansion of drug-delivery capabilities Bend Bioscience (OR, USA) and NovaQuest Private Equity, have announced plans on 11 October 2022 to invest in a new facility in Bend, Oregon. The group will focus on developing new R&D partnerships, and early phase manufacturing and development activities based on proprietary particle engineering-based drug-delivery technologies. This new facility will consist of approximately 20,000 square feet of laboratory and processing areas and it is anticipated that manufacturing and analytical capabilities will operational by the end of Q2 2023. Announcing the investment decision, Dan Dobry, Bend Bioscience’s co-founder said “We feel Bend Bioscience will fill an unmet need, offering problem solving, formulation, and manufacturing for valuable but challenging therapies and collaborating to develop new technologies for the rapidly evolving problem statements in the in pharmaceutical industry” [1].

DOI

https:// doi.org/10.4155/tde-2022-0066

Funder

This research received no external funding

Creative Commons License

Creative Commons Attribution-Share Alike 4.0 International License
This work is licensed under a Creative Commons Attribution-Share Alike 4.0 International License.

Download


Share

COinS